NCT04133519已完成不适用
The Efficacy and Safety of IBS Digital Behavioral Treatment Study
metaMe Health2 个研究点 分布在 1 个国家目标入组 378 人开始时间: 2019年10月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 378
- 试验地点
- 2
- 主要终点
- Abdominal Pain Intensity Responder
研究概览
简要总结
A Randomized, Double-Blind, Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Self-administered behavioral treatments for Adult Subjects with Symptomatic Irritable Bowel Syndrome (IBS).
详细描述
EASITx is a pivotal study comparing two self-administered behavioral treatments for irritable bowel syndrome (IBS). The active treatment in EASITx is classified as Software as a Medical Device (SaaMD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Male or female, aged 18-70
- •Confirmation of the IBS and IBS subtype diagnosis by a study site physician using Rome IV diagnostic criteria
- •Possess an iPhone Operating System (iOS) Apple or Android smartphone or iOS tablet (iPad) released in 2015 or later
- •Agreement to input information about their abdominal pain and bowel movements on a daily basis into Curebase software
- •Agreement to have their anonymized data stored in the cloud for up to 2 years after the conclusion of the study, and to have the data used for research purposes.
- •Agreement to maintain stable dosage of IBS medications during the course of treatment and not to add new IBS medication or stop current IBS medications unless directed to do so by the participants treating physician. Changes in treatment will be captured using a concomitant medication assessment.
- •Average "Worst Daily Pain Severity" of >3 on a 11-point numeric rating scale (NRS) over the full 28-day pre-treatment symptom tracking period
- •Consistent submission of Pain Severity scores via the Curebase app (data submitted on 80% or more of days in the symptom tracking window)
排除标准
- •Evidence of current structural intestinal abnormalities that better explain the participant's IBS symptoms (e.g., celiac disease, inflammatory bowel disease - Crohn's Disease and ulcerative colitis, prior abdominal surgeries such as weight loss surgery or bowel resection)
- •Medication use, other illnesses or conditions that can explain their gastrointestinal symptoms e.g.,regular narcotic use or dependency, Over The Counter (OTC) stimulant laxative dependence (i.e, progressively larger doses of Senna or Bisacodyl containing compounds are needed to produce a bowel movement), history of radiation to the abdomen.
- •Diagnosed and/or treated for a malignancy within the past 5 years (other than localized basal or squamous cell carcinomas of the skin)
- •Current psychotherapy, hypnotherapy, or cognitive behavioral therapy (CBT) for IBS
- •Inability to commit to completing all treatment sessions
- •Have an unstable extraintestinal condition whose immediate or foreseeable treatment needs would realistically interfere with study demands, e.g., ability to participate in online treatment sessions or follow daily diary.
- •Active psychiatric disorder (e.g., post-traumatic stress disorder, depression associated with high risk of suicidal behavior, psychotic or delusional disorders, dissociative disorders, or gross cognitive impairment)
- •Subjects that report a current gastrointestinal infection or an infection within the 4 weeks prior to the evaluation that would otherwise obscure IBS symptoms. In cases of gastrointestinal infection baseline evaluation will be delayed a minimum of 4 weeks until after complete recovery.
- •Current or recent use of a gut-targeted antibiotic such as Neomycin or Rifaximin during the 12 weeks prior to baseline assessment. In the case of treatment with rifaximin or neomycin, eligibility will be suspended for 12 weeks from the initial date of use.
- •Any condition that an investigator feels may interfere with the conduct of the study
结局指标
主要结局
Abdominal Pain Intensity Responder
时间窗: Baseline score (average of daily score for weeks -4 through -1) was compared to 4-weeks post-treatment (average daily score for weeks 13 through 16)
The primary endpoint of this study is abdominal pain intensity. The Instrument is a 0-10 numeric rating scale (NRS, 0= no pain, 10= worst pain). The subject is asked daily to record their "worst abdominal pain over the past 24-hours". An Abdominal Pain Intensity Responder is defined as a subject whose daily abdominal pain intensity averaged over the 4 weeks post-treatment (weeks 13 through 16) is at least 30% reduced compared to the daily abdominal pain intensity averaged over the 4 weeks pre-treatment (weeks -4 through -1).
次要结局
- Abdominal Pain Intensity(Baseline score (average of daily score for weeks -4 through -1) was compared to 4-weeks post-treatment (average daily score for weeks 13 through 16))
- Daily Stool Frequency(Baseline score (average of daily score for weeks -4 through -1) was compared to 4-weeks post-treatment (average daily score for weeks 13 through 16))
- Health-related Quality of Life Using the IBS Quality of Life (QOL) Instrument(Baseline (Week -4) to 4-weeks post-treatment (Week 16))
- Abdominal Pain Frequency(Change from baseline (weeks -4 to -1 before treatment) to 4-week post treatment period (Weeks 13-16))
- Number of Participants With >=30% Improvement in Normal Bowel Movements (Scored as 3, 4, or 5 on the Bristol Stool Form Scale)(Baseline score (average of daily score for weeks -4 through -1) was compared to 4-weeks post-treatment (average daily score for weeks 13 through 16))
- Percent Overall Work Impairment Due to IBS Based on the Work Productivity and Activity Impairment (WPAI) Questionnaire(Baseline (Week -4) to 4-weeks post-treatment (Week 16))
- Percent Overall Activity Impairment Due to IBS Based on the Work Productivity and Activity Impairment (WPAI) Questionnaire(4-weeks post-treatment (Week 16))
研究者
研究点 (2)
Loading locations...
相似试验
已完成
4 期
To study effect of IBS Sure plus tablet for IBS Acidity diarrhoea loss of appetiteCTRI/2022/04/041561Healing Hands and Herbs
已完成
1 期
Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male VolunteersHealthyNCT02273414Boehringer Ingelheim35
已完成
4 期
To determine effect of IBS sure tablet for patients suffering from IBS,Constipation etc.CTRI/2022/04/041590Healing Hands and Herbs
已完成
3 期
Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2NCT00622284Boehringer Ingelheim1,560
Unknown
不适用
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHDDuct-dependent Cyanotic Congenital Heart DiseasePatent Ductus ArteriosusNCT04291222Lifetech Scientific (Shenzhen) Co., Ltd.10